Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience.

MLA

Altamura, Claudia, et al. “Conversion from Chronic to Episodic Migraine in Patients Treated with Galcanezumab in Real Life in Italy: The 12-Month Observational, Longitudinal, Cohort Multicenter GARLIT Experience.” Journal of Neurology, vol. 269, no. 11, Nov. 2022, pp. 5848–57. EBSCOhost, https://doi.org/10.1007/s00415-022-11226-4.

APA

Altamura, C., Brunelli, N., Marcosano, M., Aurilia, C., Egeo, G., Lovati, C., Favoni, V., Perrotta, A., Maestrini, I., Schiano Di Cola, F., d’Onofrio, F., Finocchi, C., Bertuzzo, D., Bono, F., Ranieri, A., Albanese, M., Messina, R., Doretti, A., Di Piero, V., & Cevoli, S. (2022). Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. Journal of Neurology, 269(11), 5848–5857. https://doi.org/10.1007/s00415-022-11226-4

Chicago

Altamura, Claudia, Nicoletta Brunelli, Marilena Marcosano, Cinzia Aurilia, Gabriella Egeo, Carlo Lovati, Valentina Favoni, et al. 2022. “Conversion from Chronic to Episodic Migraine in Patients Treated with Galcanezumab in Real Life in Italy: The 12-Month Observational, Longitudinal, Cohort Multicenter GARLIT Experience.” Journal of Neurology 269 (11): 5848–57. doi:10.1007/s00415-022-11226-4.